Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Primaquine for Plasmodium vivax malaria treatment – Authors' reply — Ric N. Price (2020) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Primaquine for Plasmodium vivax malaria treatment – Authors' reply
Shared by
Sir Nicholas White
University of Cambridge
Primaquine for Plasmodium vivax malaria treatment – Authors' reply
Letter
2020
English
Authors
+2 more
RP
Ric N. Price
WT
Walter Taylor
KT
Kamala Thriemer
Abstract
1 min read
No abstract is provided for this article.
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Letter
2015
Global extent of chloroquine-resistant Plasmodium vivax – Authors' reply
Ric N. Price
,
Lorenz von Seidlein
,
Neena Valecha
,
François Nosten
,
J. Kevin Baird
,
Sir Nicholas White
The Lancet Infectious Diseases
Article
1988
VIVAX RELAPSE AFTER FALCIPARUM-MALARIA - REPLY
S Looareesuwan
,
Sir Nicholas White
,
S Chittamas
,
D Bunnag
,
T Harinasuta
The Lancet
Article
2011
Artesunate for severe malaria in African children – Authors' reply
Arjen M. Dondorp
,
Caterina Fanello
,
Lorenz von Seidlein
,
Nicholas Day
,
Sir Nicholas White
The Lancet
Article
2006
Artesunate versus quinine for severe falciparum malaria – Authors' reply
Sir Nicholas White
,
Arjen M. Dondorp
,
François Nosten
,
NPJ Day
The Lancet
Letter
2020
Triple artemisinin-based combination therapies for malaria: proceed with caution – Authors' reply
Rob W. van der Pluijm
,
Aung Pyae Phyo
,
Dysoley Lek
,
Sir Nicholas White
,
Arjen M. Dondorp
The Lancet
Discussion(0)
No comments yet. Be the first to comment.